Syneos Health Signs New Service Agreement With Pfizer
Syneos Health (Nasdaq: SYNH) has signed a new three-year agreement with Pfizer to provide global product development solutions. This partnership strengthens their existing relationship, with a provision for Pfizer to extend the agreement by two additional years. Financial details are undisclosed. The collaboration will leverage Syneos Health's therapeutic expertise to optimize Pfizer's portfolio, ensuring efficient product development and trial processes.
- New three-year agreement with Pfizer to provide product development solutions.
- Opportunity for Pfizer to extend the agreement by two additional years.
- Strengthening of an existing partnership, enhancing collaborative product development.
- None.
MORRISVILLE, N.C., July 13, 2020 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced that it has signed a new three-year agreement with Pfizer Inc. (NYSE: PFE) to deliver global product development solutions to support Pfizer's portfolio. Under the terms of the agreement, Pfizer has the right to extend the term for up to an additional two years. Financial details of the agreement were not disclosed.
This agreement builds on a longstanding relationship where Syneos Health has provided insights and expertise across the Clinical and Commercial continuum to support product development. The Company will continue to deliver a broad range of capabilities customized to meet Pfizer’s goals across its portfolio, including full service and FSP solutions.
“Our ability to deliver deep therapeutic expertise, while bringing forward insights that can facilitate shorter and more efficient trials, has proven to be advantageous in our work with Pfizer,” said Paul Colvin, President, Syneos Health Clinical Solutions. “This new agreement allows us to continue our collaboration to deliver flexible and innovative solutions. We are pleased to expand our Pfizer relationship to optimize their portfolio and deliver on our shared purpose to change patients’ lives.”
About Syneos Health
Syneos Health (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities. Created through the merger of two industry-leading companies – INC Research and inVentiv Health – we bring together approximately 24,000 clinical and commercial minds with the ability to support customers in more than 110 countries. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. To learn more about how we are shortening the distance from lab to life® visit syneoshealth.com.
| 49%; width: | 1%; width: | 50%; width: |
| Ronnie Speight | Danielle DeForge | |
| Senior Vice President, Investor Relations | Executive Director, External Communications | |
| +1 919 745 2745 | +1 202 210 5992 | |
| Investor.Relations@syneoshealth.com | danielle.deforge@syneoshealth.com |
